Posts

Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence.

Authors: Emily Stockings, Dino Zagic, Gabrielle Campbell, Megan Weier, Wayne D Hall, et al
Journal of Neurology, Neurosurgery & Psychiatry, July 2018

Review evidence for cannabinoids as adjunctive treatments for treatment-resistant epilepsy. Systematic search of Medline, Embase and PsycINFO was conducted in October 2017. Outcomes were: 50%+ seizure reduction, complete seizure freedom; improved quality of life (QoL). Tolerab…

A National Needs Assessment of Canadian Nurse Practitioners Regarding Cannabis for Therapeutic Purposes.

Authors: Lynda G. Balneaves, Abeer Alraja, Daniel Ziemianski, Fairleth McCuaig, Mark Ware
Cannabis and Cannabinoid Research, March 2018

Introduction: In Canada, the Access to Cannabis for Medical Purposes Regulations (ACMPR) has given nurse practitioners (NPs) the power to authorize cannabis for therapeutic purposes (CTP) to eligible patients. This expansion in NPs’ scope of practice underscores the importance…

Cannabis in Parkinson’s Disease: Hype or help?

Authors: Tina Mainka, Jan Stork, Ute Hidding, Carsten Buhmann
Fortschritte der Neurologie · Psychiatrie, February 2018

Cannabis buds and extracts as well as synthetic cannabinoids have been available on prescription to patients with severe diseases since March 2017, with the costs covered by health insurance companies.The prescription of medical marihuana is not restricted to specific symptoms…

Medical Cannabis in Parkinson Disease: Real-Life Patients’ Experience.

Authors: Yacov Balash, Lihi Bar-Lev Schleider, Amos Korczyn, Herzel Shabtai, Judith Knaani, et al
Clinical Neuropharmacology, November/December 2017

BACKGROUND: The use of medical cannabis (MC) is controversial. Support for its benefits is based on small clinical series. OBJECTIVE: The aim of this study was to report the results of a standardized interview study that retrospectively assessed the effects of MC on symptoms o…

Physicians-in-training are not prepared to prescribe medical marijuana.

Authors: Anastasia B. Evanoff, Tiffany Quan, Carolyn Dufault, Michael Awad, Laura Jean Bierut
Drug and Alcohol Dependence, 1 November 2017

BACKGROUND: While medical marijuana use is legal in more than half of U.S. states, evidence is limited about the preparation of physicians-in-training to prescribe medical marijuana. We asked whether current medical school and graduate medical educational training prepare phys…

Cannabinoids in treatment-resistant epilepsy: A review.

Authors: Brooke K. O’Connell, David Gloss, Orrin Devinsky
Epilepsy & Behavior, May 2017

Treatment-resistant epilepsy (TRE) affects 30% of epilepsy patients and is associated with severe morbidity and increased mortality. Cannabis-based therapies have been used to treat epilepsy for millennia, but only in the last few years have we begun to collect data from adequ…

Using Medical Cannabis in an Oncology Practice

Authors: Donald I. Abrams
Oncology, May 2016

As oncologists, we treat patients who have devastating diagnoses with potent therapies. Hence, we demand solid evidence before recommending any intervention. Unfortunately, when it comes to supporting the use of cannabis in clinical situations, we are frustrated by a dearth of…

Marijuana Use in Epilepsy: The Myth and the Reality.

Authors: Kamil Detyniecki, Lawrence Hirsch
Current Neurology and Neuroscience Reports, October 2015

Marijuana has been utilized as a medicinal plant to treat a variety of conditions for nearly five millennia. Over the past few years, there has been an unprecedented interest in using cannabis extracts to treat epilepsy, spurred on by a few refractory pediatric cases featured…

Medical marijuana laws and adolescent marijuana use in the USA from 1991 to 2014: results from annual, repeated cross-sectional surveys.

Authors: Deborah S. Hasin, Melanie Wall, Katherine M. Keyes, Magdalena Cerdá, John Schulenberg, et al
The Lancet Psychiatry, July 2015

BACKGROUND: Adolescent use of marijuana is associated with adverse later effects, so the identification of factors underlying adolescent use is of substantial public health importance. The relationship between US state laws that permit marijuana for medical purposes and adoles…

Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products.

Authors: Ryan Vandrey, Jeffrey C. Raber, Mark E. Raber, Brad Douglass, Cameron Miller, Marcel O. Bonn-Miller
JAMA, 23 June 2015

As the use of cannabis (marijuana) for medical purposes has expanded, a variety of edible products for oral consumption has been developed. An estimated 16% to 26% of patients using medical cannabis consume edible products.1,2 Even though oral consumption lacks the harmful by-…

Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review.

Authors: Kevin P. Hill
JAMA, 23 June 2015

IMPORTANCE: As of March 2015, 23 states and the District of Columbia had medical marijuana laws in place. Physicians should know both the scientific rationale and the practical implications for medical marijuana laws. OBJECTIVE: To review the pharmacology, indications, and law…

Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.

Authors: Penny F. Whiting, Robert F. Wolff, Sohan Deshpande, Marcello Di Nisio, Steven Duffy, et al
JAMA, 23 June 2015

IMPORTANCE: Cannabis and cannabinoid drugs are widely used to treat disease or alleviate symptoms, but their efficacy for specific indications is not clear. OBJECTIVE: To conduct a systematic review of the benefits and adverse events (AEs) of cannabinoids. DATA SOURCES: Twenty…